Methods	Randomised, double blind, parallel group, no enriched enrolment. 1-week titration for 300/600 mg (withdrawing those not able to reach target dose) (12 weeks total)
Participants	Painful diabetic neuropathy for more than 1 year, and pain at least 40/100 mm. Mean age 59 years, 44% female, 96% white
Interventions	Pregabalin 150 mg daily, n = 99 Pregabalin 300 mg daily, n = 99 Pregabalin 600 mg daily, n = 101 Placebo daily, n = 96
Outcomes	Proportion of patients with ≥ 50% decrease in mean pain score between endpoint and baseline, and other outcomes
Notes	Oxford quality score: R1, D1, W1 = 3/5 Pfizer sponsored
Risk of bias
Item	Authors’ judgement	Description
Adequate sequence generation?	Unclear	Stated to be randomised
Allocation concealment?	Unclear	Not described
Blinding? All outcomes	Unclear	Stated to be double blind